Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001817714 | SCV002069033 | uncertain significance | not specified | 2018-05-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001869783 | SCV002177462 | uncertain significance | not provided | 2021-10-16 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant is also known as p.Gly171Arg. This variant has been observed in individual(s) with autosomal dominant familial hyperinsulinism (PMID: 23506826). This variant is present in population databases (rs747928745, ExAC 0.01%). This sequence change replaces glycine with arginine at codon 149 of the HNF4A protein (p.Gly149Arg). The glycine residue is moderately conserved and there is a moderate physicochemical difference between glycine and arginine. |
Fulgent Genetics, |
RCV002478063 | SCV002780338 | uncertain significance | Maturity-onset diabetes of the young type 1; Type 2 diabetes mellitus; Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young | 2021-11-08 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001869783 | SCV005194982 | uncertain significance | not provided | criteria provided, single submitter | not provided |